Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;12(16):17365-17376.
doi: 10.1002/cam4.6355. Epub 2023 Jul 31.

The impact of COVID-19 on mortality, length of stay, and cost of care among patients with gastrointestinal malignancies: A propensity score-matched analysis

Mark B Ulanja  1 , Bryce D Beutler  2 , Kwabena Oppong Asafo-Agyei  3 , Samuel B Governor  4 , Samuel Edusa  5 , Daniel Antwi-Amoabeng  1 , Reginald N Ulanja  6 , Grace B Nteim  6 , Millicent Amankwah  7 , Vijay Neelam  1 , Ganiyu A Rahman  8 , Francis T Djankpa  6 , Tarig Mabrouk  1 , Olatunji B Alese  9
Affiliations

The impact of COVID-19 on mortality, length of stay, and cost of care among patients with gastrointestinal malignancies: A propensity score-matched analysis

Mark B Ulanja et al. Cancer Med. 2023 Aug.

Abstract

Background: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the coronavirus 19 (COVID-19) pandemic have had a lasting impact on the care of cancer patients. The impact on patients with gastrointestinal (GI) malignancies remains incompletely understood. We aimed to assess the impact of COVID-19 on mortality, length of stay (LOS), and cost of care among patients with GI malignancies, and identify differences in outcomes based on primary tumor site.

Methods: We analyzed discharge encounters collected from the National Inpatient Sample (NIS) between March 2020 and December 2020 using propensity score matching (PSM) and COVID-19 as the treatment effect.

Results: Of the 87,684 patient discharges with GI malignancies, 1892 were positive for COVID-19 (C+) and eligible for matching in the PSM model. Following PSM analysis, C+ with GI tumors demonstrated increased incidence of mortality compared to their COVID-19-negative (C-) counterparts (21.3% vs. 11.9%, p < 0.001). C+ patients with colorectal cancer (CRC) had significantly higher mortality compared to those who were C- (40% vs. 24%; p = 0.035). In addition, C+ patients with GI tumors had a longer mean LOS (9.4 days vs. 6.9 days; p < 0.001) and increased cost of care ($26,048.29 vs. $21,625.2; p = 0.001) compared to C- patients. C+ patients also had higher odds of mortality secondary to myocardial infarction relative to C- patients (OR = 3.54, p = 0.001).

Conclusions: C+ patients with GI tumors face approximately double the odds of mortality, increased LOS, and increased cost of care compared to their C- counterparts. Outcome disparities were most pronounced among patients with CRC.

Keywords: COVID-19; SARS-CoV-2; gastrointestinal cancer; healthcare cost disparity; impact of COVID-19 on gastrointestinal malignancies; mortality; propensity score-matched analysis.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Distribution of primary tumor sites in patients with and without COVID‐19.
See this image and copyright information in PMC

References

    1. Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17‐48. - PubMed
    1. Henley SJ, Dowling NF, Ahmad FB, Ellington TD, Wu M, Richardson LC. COVID‐19 and other underlying causes of cancer deaths — United States, January 2018–July 2022. MMWR Morb Mortal Wkly Rep. 2022;2022(71):1583‐1588. - PMC - PubMed
    1. Long B, Brady WJ, Koyfman A, Gottlieb M. Cardiovascular complications in COVID‐19. Am J Emerg Med. 2020;38(7):1504‐1507. - PMC - PubMed
    1. Fraser E. Long Term Respiratory Complications of Covid‐19. British Medical Journal Publishing Group; 2020. - PubMed
    1. Yang K, Sheng Y, Huang C, et al. Clinical characteristics, outcomes, and risk factors for mortality in patients with cancer and COVID‐19 in Hubei, China: a multicentre, retrospective, cohort study. Lancet Oncol. 2020;21(7):904‐913. - PMC - PubMed